Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | PTPRB | P23467 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778922 | 0.82 | SLC6A3 (0.31) | SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8870424 | 0.78 | — | — | |
| SCHEMBL5777081 | 0.76 | ABCB1 (0.50) | PTPRBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2745021 | 0.71 | LTA4H (0.38) | — | |
| SCHEMBL4848561 | 0.71 | KDR (0.39) | NPC1RAB9A | |
| SCHEMBL6177757 | 0.70 | IDO1 (0.40) | — | |
| SCHEMBL3865314 | 0.69 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7985829 | 0.68 | ADRB2 (0.34) | SLC6A3 | |
| SCHEMBL8796135 | 0.68 | TSHR (0.34) | SLC6A3SMN1; SMN2 | |
| SCHEMBL3421366 | 0.67 | CHRM2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | AHR 5/4885PTPRB 4721/4885SLC6A3 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.